Oncolytic Virus GMP Manufacturing: Solving Antibody Neutralization Challenges with Next Generation Sequencing - 21 de octubre de 2025 - TecnoWebinars.com

Ensuring viral safety in oncolytic virus manufacturing can be particularly complex when neutralizing antibodies interfere with traditional biosafety assays. In this session, we will explore how GMP NGS enables accurate detection of adventitious agents and supports risk mitigation when antibodies threaten viral safety assessment. You’ll gain insight into regulatory expectations, case studies, and how integrating NGS-based biosafety into your workflow can de-risk development and accelerate timelines. Key takeaways: Addressing antibody neutralization in oncolytic virus GMP manufacturing Enhancing biosafety with validated NGS approaches Real-world applications and regulatory insights Secure your place today and explore how GMP NGS empowers oncolytic virus manufacturers to ensure viral safety and, speed up timelines.